Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Overweight and raises the price target from $245 to $280.